Cancers, Vol. 12, Pages 773: Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia Before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse –Bordeaux DATAML Registry Study

Cancers, Vol. 12, Pages 773: Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia Before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse–Bordeaux DATAML Registry Study Cancers doi: 10.3390/cancers12040773 Authors: Sarah Bertoli Pierre-Yves Dumas Emilie Bérard Laetitia Largeaud Audrey Bidet Eric Delabesse Suzanne Tavitian Noémie Gadaud Thibaut Leguay Harmony Leroy Jean-Baptiste Rieu Jean-Philippe Vial François Vergez Nicolas Lechevalier Isabelle Luquet Emilie Klein Audrey Sarry Anne-Charlotte De Grande Christian Récher Arnaud Pigneux A recent phase 3 trial showed that the outcome of patients with relapsed/refractory (R/R) FLT3-mutated acute myeloid leukemia (AML) improved with gilteritinib, a single-agent second-generation FLT3 tyrosine kinase inhibitor (TKI), compared with standard of care. In this trial, the response rate with standard therapy was particularly low. We retrospectively assessed the characteristics and outcome of patients with R/R FLT3-mutated AML included in the Toulouse–Bordeaux DATAML registry. Among 347 patients who received FLT3 TKI-free intensive chemotherapy as first-line treatment, 174 patients were refractory (n = 48, 27.6%) or relapsed (n = 126, 72.4%). Salvage treatments consisted of intensive chemotherapy (n = 99, 56.9%), azacitidine or low-dose cytarabine (n = 9, 5.1%), other low-intensity treatments (n = 17, 9.8%), immediate allogeneic stem cell transp...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research